Meeting
2017 ASCO Annual Meeting
Effects of age, immune landscape, and response to trastuzumab (H) in HER-2 positive (HER2+) breast cancer in NCCTG (Alliance)-N9831.
Authors
Aixa Elena Soyano
Mayo Clinic Florida, Jacksonville, FL
Aixa Elena Soyano , Daniel Serie , Afshin Mashadi-Hossein , Sarah Warren , Gerardo Colon-Otero , Keith L. Knutson , Edith A. Perez , Alvaro Moreno-Aspitia , E Aubrey Thompson , Saranya Chumsri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 35, 2017 (suppl; abstr 530)
DOI
10.1200/JCO.2017.35.15_suppl.530
Abstract #
530
Poster Bd #
130
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Effect of TCHL-based therapy on immune cell content in on-treatment, neoadjuvant-treated HER2-positive breast cancer patients.
First Author: Niamh M. Keegan
Poster
2023 ASCO Annual Meeting
Neoadjuvant therapy of HER2 directed conventional dendritic cell (DC1) intratumoral (IT) therapy plus weekly paclitaxel, trastuzumab, and pertuzumab in patients with HER-2 positive breast cancer: NATASHA trial.
First Author: Hyo S. Han
Poster
2020 ASCO Virtual Scientific Program
Liquid biopsy of the immune environment: Evaluation of peripheral blood mononuclear cells (PBMCs) with CyTOF and response to trastuzumab (T)-based neoadjuvant chemotherapy (NAC) in HER2+ breast cancer (BC).
First Author: Roberto Antonio Leon-Ferre
Poster
2019 ASCO Annual Meeting
Is neratinib following trastuzumab in early-stage HER2-positive breast cancer cost-effective?
First Author: Naomi RM Schwartz